~~<i id='1393C2BDAD'><strike id='1393C2BDAD'><tt id='1393C2BDAD'><pre id='1393C2BDAD'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

comprehensive

author：fashion 2025-09-30 19:26:47 - browse：653

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： In his State of the Union, Biden takes clear aim at 'Big Pharma'

Wikipedia

hotspot

entertainment

hotspot

knowledge

AdobeThinkingaboutmessagingyourphysicianaboutaweirdrash?Youmaywanttoholdoffonit.Somehospitalsystemsh

WSS

First medicine developed to treat MASH expected to be approved soon

DeSantis talks Trump, trans issues and 'what wokeness is'

Affordable Connectivity Program vital to health care, experts say

Precocious puberty in girls comes with mental health risks

Precocious puberty in girls comes with mental health risks

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

entertainment

comprehensive

Wikipedia

Medical leaders decry Supreme Court decision on affirmative action

I learned firsthand about improving diversity in clinical trials

Peter Hotez and the public health issue of online harassment

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Continuity nursing helped my family in our darkest PICU moments

Change Healthcare cyberattack prompts Medicare loan program

United colonoscopy coverage change 'may cost lives,' doctors say

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Trump demands the U.S. pay no more for drugs than other countries … again

Novo Nordisk obesity pill bests Wegovy in early trial

hotspot

Tocagen's brain cancer gene therapy trial continues. Investors worry

7 more heat

A deep dive into Applied Therapeutics’ data, and questions on Cassava

DeSantis talks Trump, trans issues and 'what wokeness is'

UnitedHealth quietly bought dozens of outpatient centers

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

hotspot

entertainment

hotspot

knowledge